BioCentury
ARTICLE | Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

May 11, 2020 1:41 PM UTC

Activity among biotech IPOs has reached a steady drip following a slowdown for several weeks as COVID-19’s spread roiled markets earlier this year. The latest to file for a NASDAQ listing is Pliant, a clinical fibrosis company that’s seeking up to $86.3 million in its proposed offering.

Launched by Third Rock Ventures in 2016, Pliant Therapeutics Inc. is developing lead candidate PLN-74809 to treat idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The oral small molecule, a dual inhibitor of Integrins α(V)β(1) and α(V)β(6), is in two Phase IIa trials to treat IPF; a Phase IIa trial in PSC is due to start next half...

BCIQ Company Profiles

Pliant Therapeutics Inc.